FREMONT, Cali., March 29, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage specialty pharmaceutical company with proprietary microneedle patch technology for the delivery of drugs through the skin, today announced financial results for the fourth quarter and year ended December 31, 2015. The company also provided an update to its corporate strategy and partnering plans. The company announced a strategic focus on its ZP-Triptan program for the acute treatment of migraine, while pursuing partnership opportunities for its other clinical programs. As a result, the organization will streamline its operations to appropriately manage its resources.
“Over the last two years, Zosano has demonstrated proof-of-concept with three clinical programs,” said Dr. Konstantinos Alataris, Zosano’s President and Chief Executive Officer. “After a strategic review of our programs and resources, we have prioritized our efforts on advancing ZP-Triptan for the treatment of migraine. Our discussions with key opinion leaders have identified that our unique delivery mechanism has the potential to provide rapid resolution of migraine symptoms and address a significant unmet need in the migraine space. After consultation with the FDA on the regulatory requirements for approval, we believe a single pivotal efficacy study, in addition to the required safety study, will be sufficient to enable us to obtain FDA approval.”
